JP2020532955A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532955A5 JP2020532955A5 JP2020506983A JP2020506983A JP2020532955A5 JP 2020532955 A5 JP2020532955 A5 JP 2020532955A5 JP 2020506983 A JP2020506983 A JP 2020506983A JP 2020506983 A JP2020506983 A JP 2020506983A JP 2020532955 A5 JP2020532955 A5 JP 2020532955A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- stranded nucleic
- chemically modified
- acid molecule
- modified double
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims 35
- 150000007523 nucleic acids Chemical class 0.000 claims 35
- 102000039446 nucleic acids Human genes 0.000 claims 35
- 210000004027 cell Anatomy 0.000 claims 19
- 230000000692 anti-sense effect Effects 0.000 claims 16
- 230000002163 immunogen Effects 0.000 claims 14
- 108091081021 Sense strand Proteins 0.000 claims 13
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 12
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 12
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 8
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- -1 Tet2 Proteins 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 230000004048 modification Effects 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- 210000000130 stem cell Anatomy 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 4
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 claims 4
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 claims 4
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 claims 4
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 claims 4
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims 4
- 101000687343 Mus musculus PR domain zinc finger protein 1 Proteins 0.000 claims 4
- 108091008611 Protein Kinase B Proteins 0.000 claims 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 4
- 108091008874 T cell receptors Proteins 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 210000004405 cytokine-induced killer cell Anatomy 0.000 claims 4
- 210000004443 dendritic cell Anatomy 0.000 claims 4
- 230000002209 hydrophobic effect Effects 0.000 claims 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 4
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 3
- 101000840551 Homo sapiens Hexokinase-2 Proteins 0.000 claims 3
- 101001050577 Homo sapiens Kinesin-like protein KIF2A Proteins 0.000 claims 3
- 101001026214 Homo sapiens Potassium voltage-gated channel subfamily A member 5 Proteins 0.000 claims 3
- 101001048456 Homo sapiens Protein Hook homolog 2 Proteins 0.000 claims 3
- 102100023426 Kinesin-like protein KIF2A Human genes 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 108700019146 Transgenes Proteins 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 101150080074 TP53 gene Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023146785A JP2024028231A (ja) | 2017-08-07 | 2023-09-11 | 化学修飾されたオリゴヌクレオチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542043P | 2017-08-07 | 2017-08-07 | |
| US62/542,043 | 2017-08-07 | ||
| US201762558183P | 2017-09-13 | 2017-09-13 | |
| US62/558,183 | 2017-09-13 | ||
| PCT/US2018/045671 WO2019032619A1 (en) | 2017-08-07 | 2018-08-07 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146785A Division JP2024028231A (ja) | 2017-08-07 | 2023-09-11 | 化学修飾されたオリゴヌクレオチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020532955A JP2020532955A (ja) | 2020-11-19 |
| JP2020532955A5 true JP2020532955A5 (cg-RX-API-DMAC7.html) | 2021-08-26 |
Family
ID=65271710
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020506983A Pending JP2020532955A (ja) | 2017-08-07 | 2018-08-07 | 化学修飾されたオリゴヌクレオチド |
| JP2023146785A Pending JP2024028231A (ja) | 2017-08-07 | 2023-09-11 | 化学修飾されたオリゴヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146785A Pending JP2024028231A (ja) | 2017-08-07 | 2023-09-11 | 化学修飾されたオリゴヌクレオチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200215113A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3664817A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2020532955A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111201024A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018313149B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3070747A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019032619A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012502991A (ja) | 2008-09-22 | 2012-02-02 | アールエックスアイ ファーマシューティカルズ コーポレーション | 皮膚適用におけるｒｎａ干渉 |
| WO2010059226A2 (en) | 2008-11-19 | 2010-05-27 | Rxi Pharmaceuticals Corporation | Inhibition of map4k4 through rnai |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| EP2550000A4 (en) | 2010-03-24 | 2014-03-26 | Advirna Inc | RNAI COMPOUNDS OF REDUCED SIZE ADMINISTERING |
| CN106074591B (zh) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | 眼部症候中的rna干扰 |
| JP6772062B2 (ja) * | 2013-12-02 | 2020-10-21 | フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． | 癌の免疫療法 |
| US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
| US10900039B2 (en) | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
| US11001845B2 (en) | 2015-07-06 | 2021-05-11 | Phio Pharmaceuticals Corp. | Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) |
| US11021707B2 (en) | 2015-10-19 | 2021-06-01 | Phio Pharmaceuticals Corp. | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA |
| CN115135765A (zh) * | 2019-11-08 | 2022-09-30 | 菲奥医药公司 | 用于免疫治疗的靶向含布罗莫结构域之蛋白4(brd4)的经化学修饰的寡核苷酸 |
| IL298946A (en) | 2020-06-18 | 2023-02-01 | Genentech Inc | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| CN112266911B (zh) * | 2020-08-27 | 2022-07-22 | 清华大学 | 核酸分子 |
| WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
| EP4381070A2 (en) | 2021-08-04 | 2024-06-12 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides |
| WO2023015264A1 (en) | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| WO2023130021A1 (en) * | 2021-12-30 | 2023-07-06 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides with improved delivery properties |
| KR20250022049A (ko) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법 |
| WO2024064769A1 (en) * | 2022-09-21 | 2024-03-28 | Phio Pharmaceuticals Corp. | Induction of stem-like activated t cells |
| WO2025101204A1 (en) * | 2023-11-08 | 2025-05-15 | Phio Pharmaceuticals Corp. | Intratumoral targeting of pd-1 |
| WO2025117786A1 (en) * | 2023-11-28 | 2025-06-05 | Phio Pharmaceuticals Corp. | Enhanced combination immune checkpoint inhibition therapy utilizing rnai |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2314691A3 (en) * | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
| JP2012502991A (ja) * | 2008-09-22 | 2012-02-02 | アールエックスアイ ファーマシューティカルズ コーポレーション | 皮膚適用におけるｒｎａ干渉 |
| US8691971B2 (en) * | 2008-09-23 | 2014-04-08 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference |
| WO2010090762A1 (en) * | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| US9957558B2 (en) * | 2011-04-28 | 2018-05-01 | Life Technologies Corporation | Methods and compositions for multiplex PCR |
| JP6772062B2 (ja) * | 2013-12-02 | 2020-10-21 | フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． | 癌の免疫療法 |
| AU2015301460B2 (en) * | 2014-08-14 | 2021-04-08 | Novartis Ag | Treatment of cancer using GFR alpha-4 chimeric antigen receptor |
| CN107921147B (zh) * | 2015-05-05 | 2021-12-24 | 江苏命码生物科技有限公司 | 一种新的前体miRNA及其在肿瘤治疗中的应用 |
| AU2016322934A1 (en) * | 2015-09-14 | 2018-04-12 | Compass Therapeutics Llc | Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta |
-
2018
- 2018-08-07 AU AU2018313149A patent/AU2018313149B2/en active Active
- 2018-08-07 EP EP18843248.8A patent/EP3664817A4/en active Pending
- 2018-08-07 JP JP2020506983A patent/JP2020532955A/ja active Pending
- 2018-08-07 CN CN201880061531.8A patent/CN111201024A/zh active Pending
- 2018-08-07 WO PCT/US2018/045671 patent/WO2019032619A1/en not_active Ceased
- 2018-08-07 CA CA3070747A patent/CA3070747A1/en active Pending
- 2018-08-07 US US16/637,514 patent/US20200215113A1/en active Pending
-
2023
- 2023-09-11 JP JP2023146785A patent/JP2024028231A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532955A5 (cg-RX-API-DMAC7.html) | ||
| US20230285538A1 (en) | Efficacious mrna vaccines | |
| JP6993649B2 (ja) | 免疫賦活活性を有するオリゴヌクレオチド含有複合体及びその用途 | |
| US20210340543A1 (en) | Non-coding immunomodulatory dna construct | |
| US20220387585A1 (en) | Adoptive cell therapy using spherical nucleic acids (snas) | |
| JP2023179428A (ja) | メッセンジャーリボ核酸（ｍＲＮＡ）をコードする安定化された核酸 | |
| JP6083571B2 (ja) | 自己ゲル化核酸 | |
| JP2010515464A (ja) | Ｈｉｖ細胞表面受容体の標的化不活性化のための組成物および方法 | |
| HUE026020T2 (en) | Preparation for inhibiting gene expression and its uses | |
| CN103370413B (zh) | Dna表达构建体 | |
| WO2018213585A1 (en) | Conjugation of peptides to spherical nucleic acids (snas) using tracelless linkers | |
| MX2008008279A (es) | Actividad inmunoestimuladora de oligonucleotidos inmunoestimuladores palindromicos que contienen diferentes longitudes de segmentos palindromicos. | |
| CN108431228A (zh) | Tlr抑制性寡核苷酸及其用途 | |
| KR101749230B1 (ko) | 지질-dna 및 면역 조절 물질을 포함하는 자기조립 나노구조체, 및 이를 유효성분으로 포함하는 암, 감염 질환 또는 면역 질환의 치료 또는 예방용 약제학적 조성물 | |
| JPWO2021092464A5 (cg-RX-API-DMAC7.html) | ||
| CN106341978A (zh) | 用于自身免疫疗法的树突细胞的基于微球的递送和离体操作 |